CMS Needs Regulatory Science, Chief Scientist To Coordinate With US FDA, Former Official Says

Sean Tunis embraces a bigger decision-making role for CMS in product access, while FDA Commissioner nominee Robert Califf also calls for smoother FDA-CMS hand-offs, and CBER Director Peter Marks wants a quicker FDA-CDC approval and deployment process.

two lines converge
A CMS Office of Chief Scientist and Office of Regulatory Science could help it coordinate actions with the FDA, Sean Tunis argued. • Source: Alamy

The US Centers for Medicare and Medicaid Services may need a regulatory science component to improve its relationship with the Food and Drug Administration and harmonize approval and coverage policies.

Sean Tunis, a principal at Rubix Health and former CMS chief medical officer, said during the recent Innovations in Regulatory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By 

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

 
• By 

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.

More from Pink Sheet

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

Sponsored by:

A Crossroads for Global Health: Strengthening the Future of Vaccines

Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.